Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Glenn Pierce

La Jolla, CA Medical Doctor

CMS profile 2790561

939 Coast Blvd, Unit 17A, La Jolla, CA 92037

Open in the dashboard

General payments

$5,245,633

102 records reported · program years 2019–2025

Research payments

$16,191

Paid to them · 10 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Glenn Pierce of La Jolla, CA is reported in the CMS Open Payments database as having received $5,245,633 across 102 general payments and $16,191 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,455 7
2024 General $37,254 20
2024 Research $1,756 3
2023 General $22,697 14
2023 Research $2,917 1
2022 General $5,085,296 30
2021 General $9,561 9
2021 Research $805 1
2020 General $74,059 18
2020 Research $10,713 5
2019 General $311 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Glenn Pierce
  • California median
  • Middle half of California
  • National median

In program year 2025, general payments to Glenn Pierce were reported at $16,455. Among 98,626 California profiles paid that year, the median was $172 and the middle half received between $54 and $610.

Show as a table
Year Glenn Pierce California median Middle half National median
2019 $311 $161 $50–$652 $163
2020 $74,059 $114 $34–$392 $114
2021 $9,561 $137 $41–$509 $132
2022 $5,085,296 $152 $48–$573 $149
2023 $22,697 $162 $50–$581 $160
2024 $37,254 $162 $52–$583 $164
2025 $16,455 $172 $54–$610 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $5,064,471 11 payments
  2. BioMarin Pharmaceutical Inc. $108,045 34 payments
  3. Regeneron Pharmaceuticals, Inc. $39,188 29 payments
  4. Novo Nordisk Health Care AG $14,125 4 payments
  5. Swedish Orphan Biovitrum AB $6,380 1 payment
  6. CSL Behring $4,600 2 payments
  7. Grifols, S.A. $3,590 1 payment
  8. Grifols Shared Services North America, Inc. $3,300 1 payment
  9. Genentech USA, Inc. $1,041 12 payments
  10. Novo Nordisk AS $600 1 payment
  11. Other $293 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Acquisitions $5,064,347 10 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $85,040 10 payments
  3. Consulting Fee $73,616 38 payments
  4. Travel and Lodging $17,417 11 payments
  5. Education $2,833 1 payment
  6. Food and Beverage $2,380 32 payments
Products named General payments · program years 2019–2025
  1. ALTUVIIIO $6,380 1 payment
  2. Thrombate III $3,590 1 payment
  3. Albutein $3,300 1 payment
  4. HEMLIBRA $1,041 12 payments
  5. HYMPAVZI $124 1 payment
  6. BEQVEZ $124 1 payment
  7. Non-Covered Product $94 1 payment
  8. HEMGENIX $50 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $11,518 6 payments
  2. Regeneron Pharmaceuticals, Inc. $4,673 4 payments

Records

112 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record